The Zacks Analyst Blog Highlights: Biogen, Teva Pharmaceutical, Pfizer, Novartis and U.S. Bancorp – Press Releases – NASDAQ

have received prior immunosuppressant therapy and have been treated with Tysabri for more than two years are most likely to develop PML. Prior to the Canadian approval for the label update the U.S. Food and Drug Administration and the European …